Scielo RSS <![CDATA[Revista Española de Enfermedades Digestivas]]> http://scielo.isciii.es/rss.php?pid=1130-010820130003&lang=en vol. 105 num. 3 lang. en <![CDATA[SciELO Logo]]> http://scielo.isciii.es/img/en/fbpelogp.gif http://scielo.isciii.es <![CDATA[<b>Rationalizing the use of PPIs</b>: <b>An unresolved matter</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300001&lng=en&nrm=iso&tlng=en <![CDATA[<b>Laparoscopic common bile duct exploration and antegrade biliary stenting</b>: <b>Leaving behind the Kehr tube</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300002&lng=en&nrm=iso&tlng=en Introduction: single-stage laparoscopic surgery of cholelithiasis and associated common bile duct stones (CL-CBDS) has shown similar results when compared to laparoscopic cholecystectomy combined with ERCP. Classically, choledochorrhaphy has been protected by a T-tube drain to allow external bypass of bile flow. However, its removal is associated with a significant complication rate. Use of antegrade biliary stents avoids T-tube removal associated morbidity. The aim of this study is to compare the results of choledochorrhaphy plus T-tube drainage versus antegrade biliary stenting in our series of laparoscopic common bile duct explorations (LCBDE). Material and methods: between 2004 and 2011, 75 patients underwent a LCBDE. Choledochorrhaphy was performed following Kehr tube placements in 47 cases and transpapillary biliary stenting was conducted in the remaining 28 patients. Results: postoperative hospital stay was shorter in the stent group (5 ± 10.26 days) than in the Kehr group (12 ± 10.6 days), with a statistically significant difference. There was a greater trend to grade B complications in the stent group (10.7 vs. 4.3 %) and to grade C complications in the Kehr group (6.4 vs. 3.6 %). There were 3 cases of residual common bile duct stones in the Kehr group (6.4 %) and none in the stent group. Conclusions: antegrade biliary stenting following laparoscopic common bile duct exploration for CL-CBDS is an effective and safe technique that prevents T-tube related morbidity.<hr/>Introducción: el tratamiento de la colecisto-coledocolitiasis por vía laparoscópica en un tiempo ha demostrado resultados comparables a la colecistectomía laparoscópica asociada a CPRE. Clásicamente, la coledocorrafia se ha realizado sobre un tubo en T para permitir la derivación externa del flujo biliar. Sin embargo, su retirada está asociada a una significativa tasa de complicaciones. El uso de prótesis biliares anterógradas, evita toda la morbilidad asociada a la retirada del tubo en T. En este estudio, comparamos los resultados entre la coledocorrafia sobre Kehr vs. prótesis biliar en nuestra serie de colédoco-litotomía laparoscópica. Material y métodos: entre 2004 y 2011, hemos intervenido 75 pacientes de colecisto-coledocolitiasis por vía laparoscópica, realizando en 47 casos la coledocorrafia sobre un tubo de Kehr y sobre prótesis biliar transpapilar en los 28 restantes. Resultados: la estancia postoperatoria fue menor en el grupo prótesis (5 ± 10,26 días) que en el grupo Kehr (12 ± 10,6 días), siendo estadísticamente significativa. Se observó una mayor tendencia a las complicaciones grado B en el grupo prótesis (10,7 vs. 4,3 %) y complicaciones grado C en el grupo Kehr (6,4 vs. 3,6 %). La tasa de coledocolitiasis residual fue de 3 casos en el grupo Kehr (6,4 %) y ninguno en el grupo prótesis. Conclusiones: la coledocorrafia sobre prótesis biliar transpapilar por vía laparoscópica es una técnica efectiva y segura para el tratamiento de la colecisto-coledocolitiasis en un único tiempo, evitando todas las complicaciones derivadas del manejo y retirada del tubo de Kehr. <![CDATA[<b>Inadequate prescription of chronic consumption of proton pump inhibitors in a hospital in Mexico</b>: <b>Cross-sectional study</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300003&lng=en&nrm=iso&tlng=en Introduction: PPIs have been an enormous therapeutic advance in acid-related diseases. However, it has been detected an abuse in its consumption. The aim of this study was to determine the frequency of inadequate prescription of chronic use of PPIs in outpatients in a speciality hospital. Material and methods: we performed a cross-sectional descriptive study review. The study population were patients, chronic users of proton pump inhibitors (PPIs), attending outpatient consult in a hospital of government workers. We defined as chronic user of PPIs that patient that takes medication daily for over a year and inappropriate prescription, that one that has not been approved by the clinical guidelines. A simple random sampling was utilized. The following parameters were investigated: diagnosis and prescription of PPIs, time of use, at which level of care PPIs were prescribed (primary care or specialist), self-medication, with or without endoscopy. For the statistical analysis, we used Student's t-test and Chi-square, 95% confidence intervals and significance 0.05 %. Results: we reviewed 153 patients, 40 (26.1 %) men and 113 (73.9 %) women, mean age 58 ± 11.4 years. The prescription of chronic treatment with PPIs was adequate in 64.7 % of patients and inadequate in 35.3 %. The most common appropriate prescription (31.3 %) of chronic use of PPIs was due to gastroesophageal reflux disease. The most common inadequate prescription was absence of diagnosis (22.2 %), polypharmacy without nonsteroidal antiinflammatory drugs (16.6 %) and chronic gastritis (16.6 %). History of endoscopy were not statistically significant. Conclusions: the frequency of inappropriate prescriptions of chronic use of PPIs was high, around 35.3 %, similar to those reported in hospitals in developed countries.<hr/>Introducción: los IBP han sido un avance terapéutico enorme en las enfermedades relacionadas con el ácido. Sin embargo se ha detectado que hay mayoritariamente un abuso en su consumo. El objetivo del estudio fue determinar en nuestro medio la frecuencia de indicación inadecuada en el consumo crónico de IBP en pacientes ambulatorios en un hospital de especialidades. Material y métodos: se realizó un estudio de revisión transversal descriptivo. La población estudiada fueron pacientes de un hospital de trabajadores del Estado, consumidores crónicos de IBP que acudieron a consulta externa. Se definió como consumidor crónico de IBP la toma diaria del medicamento durante más de un año e indicación inadecuada (no aprobada por guías clínicas). El muestreo fue aleatorio simple. Se investigaron los siguientes parámetros: diagnóstico e indicación de los IBP, tiempo de uso, en qué nivel de atención se prescribió (atención primaria o especializada), automedicación, con o sin endoscopia digestiva. Para el análisis estadístico se utilizó t de Student y Chi cuadrado, intervalos de confianza 95 % y significancia 0,05 %. Resultados: se revisaron 153 pacientes, 40 (26,1 %) hombres y 113 (73,9 %) mujeres, edad promedio 58 (DE 11,4) años. La indicación de tratamiento crónico con IBP era adecuada en el 64,7 % de los pacientes e inadecuada en el 35,3 %. La indicación apropiada más frecuente (31,3 %) del consumo crónico de IBP fue la ERGE. La indicación inadecuada más frecuente fue la prescripción sin diagnóstico (22,2 %), polifarmacia sin AINE (16,6 %) y gastritis crónica (16,6 %. Antecedentes de endoscopia no tuvieron significación estadística (p > 0,05). Conclusiones: la frecuencia de indicaciones inadecuadas en el consumo crónico de IBP fue alta y del 35,3%, similar a los publicados en hospitales de países desarrollados. <![CDATA[<b>Preparation of a three-dimensional extracellular matrix by decellularization of rabbit livers</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300004&lng=en&nrm=iso&tlng=en Introduction: the availability of transplantable livers is not sufficient to fulfill the current demand for grafts, with the search for therapeutic alternatives having generated different lines of research, one of which is the use of decellularized three-dimensional biological matrices and subsequent cell seeding to obtain a functional organ. Objective: to produce a decellularization protocol from rabbit liver to generate a three-dimensional matrix. Methods: a combination of physical, chemical (Triton X-100 and SDS) and enzymatic agents to decellularize rabbit livers was used. After 68 h of retrograde perfusion, a decellularized translucent matrix was generated. To evaluate if the decellularization protocol was successful, with the extracellular matrix being preserved, we carried out histological (light microscopy and scanning electron microscopy) and biochemical (DNA quantification) studies. Results: the decellularization process was verified by macroscopic observation of the organ using macroscopic staining, which revealed a correct conservation of bile and vascular trees. A microscopic observation corroborated these macroscopic results, with the hematoxylin-eosin staining showing no cells or nuclear material and the presence of a portal triad. Wilde's staining demonstrated the conservation of reticulin fibers in the decellularized matrix. In addition, scanning electron microscopy revealed a preserved Glisson's capsule and a decellularized matrix, with the DNA quantification being less than 10 % in the decellularized liver compared to control. Finally, the time taken to develop the decellularization protocol was less than 96 hours. Conclusions: the proposed decellularization protocol was correct, and was verified by an absence of cells. The hepatic matrix had preserved vascular and bile ducts with a suitable three-dimensional architecture permitting further cell seeding.<hr/>Introducción: el número de hígados trasplantables es insuficiente para satisfacer las necesidades actuales de la demanda de injerto. La búsqueda de alternativas terapéuticas ha generado diferentes líneas de investigación, una de ellas es la utilización de matrices biológicas tridimensionales descelularizadas y la posterior siembra celular para obtener un órgano funcional. Objetivo: obtención de un protocolo de descelularización de hígado de conejo que genere una matriz hepática tridimensional. Métodos: una combinación de detergentes (Triton X-100 y SDS), agentes físicos y enzimáticos se utilizaron para descelularizar hígados de conejo. Los órganos se pefundieron en forma retrógrada con distintos agentes químicos durante 68 horas. Luego los hígados se examinaron por técnicas morfológicas (microscopía óptica y electrónica de barrido) y bioquímicas (cuantificación de ADN) para evaluar una correcta descelularización así como la obtención de una matriz extracelular preservada. Resultados: la observación macroscópica del órgano permitió inferir la descelularización del mismo. Las tinciones macroscópicas utilizadas mostraron una correcta conservación de los árboles biliar y vascular. Por otro lado, la observación microscópica del hígado permitió corroborar los resultados macroscópicos observados, la tinción de hematoxilina-eosina mostró ausencia de células y de material nuclear así como la presencia de la tríada portal. La tinción de Wilde evidenció la conservación de las fibras de reticulina en la matriz descelularizada. Asimismo, la microscopía electrónica de barrido reveló una cápsula de Glisson conservada y la descelularización de la cuantificación de ADN fue inferior al 10 % en el hígado descelularizado con respecto al hígado control. Finalmente, el tiempo utilizado para la descelularización fue inferior a las 96 horas. Conclusiones: el protocolo de descelularización propuesto fue apropiado ya que se verificó una ausencia de células y una matriz hepática con conductos vasculobiliares conservados y con una arquitectura tridimensional adecuada para una futura siembra celular. <![CDATA[<b>Questionnaires for measuring fatigue and its impact on health perception in inflammatory bowel disease</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300005&lng=en&nrm=iso&tlng=en Introduction: fatigue impacts perceived health, but its importance in inflammatory bowel disease is not known. Objectives: to define the applicability of the fatigue measurement questionnaires and analyze it in patients with Crohn's disease and ulcerative colitis. Material and methods: in a first phase, the psychometric properties of 3 fatigue measurement questionnaires were determined in 99 patients: Daily Fatigue Impact Scale, Fatigue Severity Scale, and Modified Fatigue Impact Scale. In a second phase, fatigue status and its relationship to disease and quality of life was determined in 127 patients and 69 healthy controls. Results: the first part of the study showed the applicability of the questionnaires listed in inflammatory bowel disease, the Daily Fatigue Impact Scale (DFIS) having the best correlation with the quality of life and clinical activity. In the second phase, significantly higher levels of fatigue were observed in active disease than in disease in remission and healthy controls (p < 0,05). The severity of fatigue was significantly correlated with quality of life (r = -0.66 and -0.72 between IBDQ-9 and DFIS and in Crohn's disease and ulcerative colitis, respectively) and with disease activity (r = 0.25 and Crohn's disease and ulcerative colitis, respectively, p < 0.05). Conclusions: in inflammatory bowel disease, fatigue measurement questionnaires have good properties and show that fatigue is an important manifestation of the disease, which has a significant impact on quality of life of patients.<hr/>Introducción: la fatiga repercute en la salud percibida, pero se desconoce su relevancia en la enfermedad inflamatoria intestinal. Objetivos: definir la aplicabilidad de cuestionarios de medida de fatiga y analizarla en pacientes con enfermedad de Crohn y colitis ulcerosa. Material y métodos: en una primera fase, en 99 pacientes se determinaron las propiedades psicométricas de 3 cuestionarios de medida de fatiga: Escala del Impacto Diario de Fatiga, Escala de Gravedad de la Fatiga y Escala Modificada del Impacto de Fatiga. En una segunda fase, se determinó el estado de fatiga y su relación con la enfermedad y la calidad de vida en 127 pacientes y 69 controles sanos. Resultados: la primera parte del estudio, demostró la aplicabilidad de los cuestionarios citados en la enfermedad inflamatoria intestinal, siendo la Escala del Impacto Diario de Fatiga (EIDF) el de mejor correlación con la calidad de vida y la actividad clínica. En la segunda fase, se objetivaron unos niveles significativamente superiores de fatiga en la enfermedad activa que en la enfermedad en remisión y los controles sanos (p < 0,05). La intensidad de la fatiga se correlacionó de forma significativa con la calidad de vida (r = -0,66 y -0,72 entre el IBDQ-9 y EIDF en enfermedad de Crohn y colitis ulcerosa respectivamente) y con la actividad de la enfermedad (r = 0,25 y 0,33 en la enfermedad de Crohn y colitis ulcerosa respectivamente, p < 0,05). Conclusiones: en la enfermedad inflamatoria intestinal los cuestionarios de medida de fatiga tienen propiedades adecuadas y demuestran que la fatiga es una manifestación importante de la enfermedad, que repercute de forma significativa en la calidad de vida de los pacientes. <![CDATA[<b>Bone mineral density in adult coeliac disease</b>: <b>An updated review</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300006&lng=en&nrm=iso&tlng=en Introduction and objectives: coeliac disease (CD) affects around 1-2 % of the world population. Most patients are now diagnosed when adults, suffering the consequences of an impaired bone mineralization. This review aims to provide an updated discussion on the relationship between low bone mineral density (BMD), osteopenia and osteoporosis, and CD. Methods: a PubMed search restricted to the last 15 years was conducted. Sources cited in the results were also reviewed to identify potential sources of information. Results: low BMD affects up to 75 % of celiac patients, and can be found at any age, independently of positive serological markers and presence of digestive symptoms. The prevalence of CD among osteoporotic patients is also significantly increased. Two theories try to explain this origin of low BMD: Micronutrients malabsorption (including calcium and vitamin D) determined by villous atrophy has been related to secondary hyperparathyroidism and incapacity to achieve the potential bone mass peak; chronic inflammation was also related with RANKL secretion, osteoclasts activation and increased bone resorption. As a consequence, celiac patients have a risk for bone fractures that exceed 40 % that of matched non-affected population. Treatment of low BMD in CD comprises gluten-free diet, calcium and vitamin D supplementation, and biphosphonates, although its effects on CD have not been specifically assessed. Conclusions: up to 75 % of celiac patients and 40 % of that diagnosed in adulthood present a low BMD and a variable increase in the risk of bone fractures. Epidemiological changes in CD make bone density scans more relevant for adult coeliacs. <![CDATA[<b>Double endosonography-guided transgastric and transduodenal drainage of infected pancreatic-fluid collections using metallic stents</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300007&lng=en&nrm=iso&tlng=en Introduction and objectives: coeliac disease (CD) affects around 1-2 % of the world population. Most patients are now diagnosed when adults, suffering the consequences of an impaired bone mineralization. This review aims to provide an updated discussion on the relationship between low bone mineral density (BMD), osteopenia and osteoporosis, and CD. Methods: a PubMed search restricted to the last 15 years was conducted. Sources cited in the results were also reviewed to identify potential sources of information. Results: low BMD affects up to 75 % of celiac patients, and can be found at any age, independently of positive serological markers and presence of digestive symptoms. The prevalence of CD among osteoporotic patients is also significantly increased. Two theories try to explain this origin of low BMD: Micronutrients malabsorption (including calcium and vitamin D) determined by villous atrophy has been related to secondary hyperparathyroidism and incapacity to achieve the potential bone mass peak; chronic inflammation was also related with RANKL secretion, osteoclasts activation and increased bone resorption. As a consequence, celiac patients have a risk for bone fractures that exceed 40 % that of matched non-affected population. Treatment of low BMD in CD comprises gluten-free diet, calcium and vitamin D supplementation, and biphosphonates, although its effects on CD have not been specifically assessed. Conclusions: up to 75 % of celiac patients and 40 % of that diagnosed in adulthood present a low BMD and a variable increase in the risk of bone fractures. Epidemiological changes in CD make bone density scans more relevant for adult coeliacs. <![CDATA[<b>Gastric plasmablastic lymphoma in HIV-negative patient</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300008&lng=en&nrm=iso&tlng=en Introduction and objectives: coeliac disease (CD) affects around 1-2 % of the world population. Most patients are now diagnosed when adults, suffering the consequences of an impaired bone mineralization. This review aims to provide an updated discussion on the relationship between low bone mineral density (BMD), osteopenia and osteoporosis, and CD. Methods: a PubMed search restricted to the last 15 years was conducted. Sources cited in the results were also reviewed to identify potential sources of information. Results: low BMD affects up to 75 % of celiac patients, and can be found at any age, independently of positive serological markers and presence of digestive symptoms. The prevalence of CD among osteoporotic patients is also significantly increased. Two theories try to explain this origin of low BMD: Micronutrients malabsorption (including calcium and vitamin D) determined by villous atrophy has been related to secondary hyperparathyroidism and incapacity to achieve the potential bone mass peak; chronic inflammation was also related with RANKL secretion, osteoclasts activation and increased bone resorption. As a consequence, celiac patients have a risk for bone fractures that exceed 40 % that of matched non-affected population. Treatment of low BMD in CD comprises gluten-free diet, calcium and vitamin D supplementation, and biphosphonates, although its effects on CD have not been specifically assessed. Conclusions: up to 75 % of celiac patients and 40 % of that diagnosed in adulthood present a low BMD and a variable increase in the risk of bone fractures. Epidemiological changes in CD make bone density scans more relevant for adult coeliacs. <![CDATA[<b>Treatment with adalimumab in a patient with regenerative nodular hyperplasia secondary to azathioprine</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300009&lng=en&nrm=iso&tlng=en Introduction: regenerative nodular hyperplasia (RNH) is a rare liver disease with an etiology that is not well understood. Among the etiological factors are purine-analogue drugs such as azathioprine. Case report: we present a case of a 47-year-old patient diagnosed with Crohn's disease in treatment with azathioprine due to corticosteroid dependency who developed RNH with clinical and laboratory signs of portal hypertension one year after starting treatment. After discontinuation of azathioprine, the patient started treatment and, given the poor disease progression, started treatment with adalimumab. This was continued with an excellent response and without deleterious effects on the liver. Discussion: the relevance of this case is twofold: First, this is a rare and early side effect of azathioprine treatment and this is an irreversible disease with potentially serious complications. Second, because treatment was carried out with biological drugs (adalimumab) despite the patient having advance liver disease with portal hypertension without any evidence of its worsening, nor signs of deleterious effects or complications, given that there is scarce or no experience with adalimumab treatment in this type of situation.<hr/>Introducción: la hiperplasia nodular regenerativa (HNR) es una rara enfermedad hepática de etiología no bien conocida. Entre los factores etiológicos se encuentran los fármacos análogos de las purinas, como la azatioprina. Caso clínico: presentamos un caso de un paciente de 47 años de edad diagnosticado de enfermedad de Crohn en tratamiento con azatioprina por corticodependencia que desarrolló una HNR con datos clínicos y analíticos de hipertensión portal al año del inicio del tratamiento. Tras la suspensión de la azatioprina inició tratamiento y dada la mala evolución de su enfermedad se inició tratamiento con adalimumab, el cual mantiene con excelente respuesta y sin efectos deletéreos a nivel hepático. Discusión: la relevancia del caso es doble; primero por ser un efecto secundario raro y precoz del tratamiento con azatioprina y tratarse de una enfermedad irreversible y con complicaciones potenciales graves; segundo por realizarse tratamiento de mantenimiento con fármacos biológicos (adalimumab) a pesar de padecer una hepatopatía avanzada con hipertensión portal sin evidenciarse peor evolución de esta, ni efectos deletéreos o complicaciones, dado que existe escasa o nula experiencia de tratamiento con adalimumab en este tipo de situaciones. <![CDATA[<b>Collagenous sprue</b>: <b>Don't forget connective tissue in chronic diarrhea evaluation</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300010&lng=en&nrm=iso&tlng=en Collagenous sprue is a rare disease of the small bowel characterized by mucosal atrophy and excessive subepithelial collagen deposition. The etiology remains unclear and the diagnosis is based upon patient's clinical picture and anatomopathological findings. Clinically, collagenous sprue is characterized by persistent diarrhoea, severe malabsorption, multiple nutrient deficiencies and progressive weight loss. Differential diagnosis includes celiac disease, which is mandatory to rule out because of their frequent association. Gluten-free diet is the first therapeutic step, but it usually is not effective. However, recent studies show high success rates with immunomodulators, mainly corticosteroids. We report the case of a patient presenting with chronic diarrhea and severe malabsorption who was diagnosed with collagenous sprue, with no response to gluten free diet, but with excellent response to budesonida.<hr/>El esprúe colágeno es una patología infrecuente del intestino delgado caracterizada por atrofia de la mucosa y depósito excesivo de colágeno a nivel subepitelial. Su etiología es desconocida y su diagnóstico se realiza en base a la presencia tanto de un cuadro clínico compatible como de hallazgos anatomopatógicos sugestivos. Los pacientes suelen presentar diarrea crónica, malabsorción, deficiencias nutricionales graves y una marcada pérdida ponderal. Dentro del diagnóstico diferencial es mandatorio descartar enfermedad celiaca por su frecuente asociación a la misma. La dieta sin gluten es el primer escalón terapéutico, pero generalmente no es efectiva. Sin embargo, estudios recientes señalan altas tasas de éxito mediante el uso de inmunomoduladores. Presentamos el caso de un paciente con diarrea crónica y malabsorción grave diagnosticado de esprúe colágeno, sin respuesta a la dieta sin gluten, en el que el tratamiento con budesonida ha conseguido una excelente respuesta. <![CDATA[<b>Ogilvie syndrome</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300011&lng=en&nrm=iso&tlng=en Collagenous sprue is a rare disease of the small bowel characterized by mucosal atrophy and excessive subepithelial collagen deposition. The etiology remains unclear and the diagnosis is based upon patient's clinical picture and anatomopathological findings. Clinically, collagenous sprue is characterized by persistent diarrhoea, severe malabsorption, multiple nutrient deficiencies and progressive weight loss. Differential diagnosis includes celiac disease, which is mandatory to rule out because of their frequent association. Gluten-free diet is the first therapeutic step, but it usually is not effective. However, recent studies show high success rates with immunomodulators, mainly corticosteroids. We report the case of a patient presenting with chronic diarrhea and severe malabsorption who was diagnosed with collagenous sprue, with no response to gluten free diet, but with excellent response to budesonida.<hr/>El esprúe colágeno es una patología infrecuente del intestino delgado caracterizada por atrofia de la mucosa y depósito excesivo de colágeno a nivel subepitelial. Su etiología es desconocida y su diagnóstico se realiza en base a la presencia tanto de un cuadro clínico compatible como de hallazgos anatomopatógicos sugestivos. Los pacientes suelen presentar diarrea crónica, malabsorción, deficiencias nutricionales graves y una marcada pérdida ponderal. Dentro del diagnóstico diferencial es mandatorio descartar enfermedad celiaca por su frecuente asociación a la misma. La dieta sin gluten es el primer escalón terapéutico, pero generalmente no es efectiva. Sin embargo, estudios recientes señalan altas tasas de éxito mediante el uso de inmunomoduladores. Presentamos el caso de un paciente con diarrea crónica y malabsorción grave diagnosticado de esprúe colágeno, sin respuesta a la dieta sin gluten, en el que el tratamiento con budesonida ha conseguido una excelente respuesta. <![CDATA[<b>Solid pseudopapillary neoplasm of the pancreas or Frantz's tumour</b>: <b>Report of two cases with different locations</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300012&lng=en&nrm=iso&tlng=en Collagenous sprue is a rare disease of the small bowel characterized by mucosal atrophy and excessive subepithelial collagen deposition. The etiology remains unclear and the diagnosis is based upon patient's clinical picture and anatomopathological findings. Clinically, collagenous sprue is characterized by persistent diarrhoea, severe malabsorption, multiple nutrient deficiencies and progressive weight loss. Differential diagnosis includes celiac disease, which is mandatory to rule out because of their frequent association. Gluten-free diet is the first therapeutic step, but it usually is not effective. However, recent studies show high success rates with immunomodulators, mainly corticosteroids. We report the case of a patient presenting with chronic diarrhea and severe malabsorption who was diagnosed with collagenous sprue, with no response to gluten free diet, but with excellent response to budesonida.<hr/>El esprúe colágeno es una patología infrecuente del intestino delgado caracterizada por atrofia de la mucosa y depósito excesivo de colágeno a nivel subepitelial. Su etiología es desconocida y su diagnóstico se realiza en base a la presencia tanto de un cuadro clínico compatible como de hallazgos anatomopatógicos sugestivos. Los pacientes suelen presentar diarrea crónica, malabsorción, deficiencias nutricionales graves y una marcada pérdida ponderal. Dentro del diagnóstico diferencial es mandatorio descartar enfermedad celiaca por su frecuente asociación a la misma. La dieta sin gluten es el primer escalón terapéutico, pero generalmente no es efectiva. Sin embargo, estudios recientes señalan altas tasas de éxito mediante el uso de inmunomoduladores. Presentamos el caso de un paciente con diarrea crónica y malabsorción grave diagnosticado de esprúe colágeno, sin respuesta a la dieta sin gluten, en el que el tratamiento con budesonida ha conseguido una excelente respuesta. <![CDATA[<b>Right-sided paraduodenal hernia</b>: <b>Rare cause of recurrent abdominal pain</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300013&lng=en&nrm=iso&tlng=en Collagenous sprue is a rare disease of the small bowel characterized by mucosal atrophy and excessive subepithelial collagen deposition. The etiology remains unclear and the diagnosis is based upon patient's clinical picture and anatomopathological findings. Clinically, collagenous sprue is characterized by persistent diarrhoea, severe malabsorption, multiple nutrient deficiencies and progressive weight loss. Differential diagnosis includes celiac disease, which is mandatory to rule out because of their frequent association. Gluten-free diet is the first therapeutic step, but it usually is not effective. However, recent studies show high success rates with immunomodulators, mainly corticosteroids. We report the case of a patient presenting with chronic diarrhea and severe malabsorption who was diagnosed with collagenous sprue, with no response to gluten free diet, but with excellent response to budesonida.<hr/>El esprúe colágeno es una patología infrecuente del intestino delgado caracterizada por atrofia de la mucosa y depósito excesivo de colágeno a nivel subepitelial. Su etiología es desconocida y su diagnóstico se realiza en base a la presencia tanto de un cuadro clínico compatible como de hallazgos anatomopatógicos sugestivos. Los pacientes suelen presentar diarrea crónica, malabsorción, deficiencias nutricionales graves y una marcada pérdida ponderal. Dentro del diagnóstico diferencial es mandatorio descartar enfermedad celiaca por su frecuente asociación a la misma. La dieta sin gluten es el primer escalón terapéutico, pero generalmente no es efectiva. Sin embargo, estudios recientes señalan altas tasas de éxito mediante el uso de inmunomoduladores. Presentamos el caso de un paciente con diarrea crónica y malabsorción grave diagnosticado de esprúe colágeno, sin respuesta a la dieta sin gluten, en el que el tratamiento con budesonida ha conseguido una excelente respuesta. <![CDATA[<b>Sigmoid volvulus as a presentation of neuronal intestinal dysplasia type B in an adolescent</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300014&lng=en&nrm=iso&tlng=en Collagenous sprue is a rare disease of the small bowel characterized by mucosal atrophy and excessive subepithelial collagen deposition. The etiology remains unclear and the diagnosis is based upon patient's clinical picture and anatomopathological findings. Clinically, collagenous sprue is characterized by persistent diarrhoea, severe malabsorption, multiple nutrient deficiencies and progressive weight loss. Differential diagnosis includes celiac disease, which is mandatory to rule out because of their frequent association. Gluten-free diet is the first therapeutic step, but it usually is not effective. However, recent studies show high success rates with immunomodulators, mainly corticosteroids. We report the case of a patient presenting with chronic diarrhea and severe malabsorption who was diagnosed with collagenous sprue, with no response to gluten free diet, but with excellent response to budesonida.<hr/>El esprúe colágeno es una patología infrecuente del intestino delgado caracterizada por atrofia de la mucosa y depósito excesivo de colágeno a nivel subepitelial. Su etiología es desconocida y su diagnóstico se realiza en base a la presencia tanto de un cuadro clínico compatible como de hallazgos anatomopatógicos sugestivos. Los pacientes suelen presentar diarrea crónica, malabsorción, deficiencias nutricionales graves y una marcada pérdida ponderal. Dentro del diagnóstico diferencial es mandatorio descartar enfermedad celiaca por su frecuente asociación a la misma. La dieta sin gluten es el primer escalón terapéutico, pero generalmente no es efectiva. Sin embargo, estudios recientes señalan altas tasas de éxito mediante el uso de inmunomoduladores. Presentamos el caso de un paciente con diarrea crónica y malabsorción grave diagnosticado de esprúe colágeno, sin respuesta a la dieta sin gluten, en el que el tratamiento con budesonida ha conseguido una excelente respuesta. <![CDATA[<b>A rare case of collision tumor combined with multiple primary squamous carcinomas</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300015&lng=en&nrm=iso&tlng=en Collagenous sprue is a rare disease of the small bowel characterized by mucosal atrophy and excessive subepithelial collagen deposition. The etiology remains unclear and the diagnosis is based upon patient's clinical picture and anatomopathological findings. Clinically, collagenous sprue is characterized by persistent diarrhoea, severe malabsorption, multiple nutrient deficiencies and progressive weight loss. Differential diagnosis includes celiac disease, which is mandatory to rule out because of their frequent association. Gluten-free diet is the first therapeutic step, but it usually is not effective. However, recent studies show high success rates with immunomodulators, mainly corticosteroids. We report the case of a patient presenting with chronic diarrhea and severe malabsorption who was diagnosed with collagenous sprue, with no response to gluten free diet, but with excellent response to budesonida.<hr/>El esprúe colágeno es una patología infrecuente del intestino delgado caracterizada por atrofia de la mucosa y depósito excesivo de colágeno a nivel subepitelial. Su etiología es desconocida y su diagnóstico se realiza en base a la presencia tanto de un cuadro clínico compatible como de hallazgos anatomopatógicos sugestivos. Los pacientes suelen presentar diarrea crónica, malabsorción, deficiencias nutricionales graves y una marcada pérdida ponderal. Dentro del diagnóstico diferencial es mandatorio descartar enfermedad celiaca por su frecuente asociación a la misma. La dieta sin gluten es el primer escalón terapéutico, pero generalmente no es efectiva. Sin embargo, estudios recientes señalan altas tasas de éxito mediante el uso de inmunomoduladores. Presentamos el caso de un paciente con diarrea crónica y malabsorción grave diagnosticado de esprúe colágeno, sin respuesta a la dieta sin gluten, en el que el tratamiento con budesonida ha conseguido una excelente respuesta. <![CDATA[<b>Severe rhabdomyolysis and hyponatremia induced by picosulfate and bisacodyl during the preparation of colonoscopy</b>]]> http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000300016&lng=en&nrm=iso&tlng=en Collagenous sprue is a rare disease of the small bowel characterized by mucosal atrophy and excessive subepithelial collagen deposition. The etiology remains unclear and the diagnosis is based upon patient's clinical picture and anatomopathological findings. Clinically, collagenous sprue is characterized by persistent diarrhoea, severe malabsorption, multiple nutrient deficiencies and progressive weight loss. Differential diagnosis includes celiac disease, which is mandatory to rule out because of their frequent association. Gluten-free diet is the first therapeutic step, but it usually is not effective. However, recent studies show high success rates with immunomodulators, mainly corticosteroids. We report the case of a patient presenting with chronic diarrhea and severe malabsorption who was diagnosed with collagenous sprue, with no response to gluten free diet, but with excellent response to budesonida.<hr/>El esprúe colágeno es una patología infrecuente del intestino delgado caracterizada por atrofia de la mucosa y depósito excesivo de colágeno a nivel subepitelial. Su etiología es desconocida y su diagnóstico se realiza en base a la presencia tanto de un cuadro clínico compatible como de hallazgos anatomopatógicos sugestivos. Los pacientes suelen presentar diarrea crónica, malabsorción, deficiencias nutricionales graves y una marcada pérdida ponderal. Dentro del diagnóstico diferencial es mandatorio descartar enfermedad celiaca por su frecuente asociación a la misma. La dieta sin gluten es el primer escalón terapéutico, pero generalmente no es efectiva. Sin embargo, estudios recientes señalan altas tasas de éxito mediante el uso de inmunomoduladores. Presentamos el caso de un paciente con diarrea crónica y malabsorción grave diagnosticado de esprúe colágeno, sin respuesta a la dieta sin gluten, en el que el tratamiento con budesonida ha conseguido una excelente respuesta.